compounding pharmacy and tirzepatide May 18, 2026: FDA warns 503B for producing after shortage ended – Partnership for Safe Medicines A Closer Look Into Compounded

We are not a compounding pharmacy or compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act, nor are we an outsourcing facility as defined under Section 503B

Diabetes Clinical Data Management Study Group

Twice-daily injections

FDA have published safety alerts on compounded GLP-1 products covering dose errors, sterility issues and ingredient mismatches

Quality Assurance + Quality Assurance Close Premium Quality Guaranteed Since 2001 BIOVEA is committed to product quality through every step of the manufacturing process: formula development, raw ingredient selection, product testing, controlled storage and transport